NCT03279328

Brief Summary

This proposed project will be an open-label, split face, randomized controlled pilot study. Up to 60 patients with diffuse facial actinic keratosis will be enrolled in the study. The purpose of this study is to understand the change in skin appearance throughout 5-FU treatment course and to examine whether a topical corticosteroid and moisturizer can decrease severity and duration of skin inflammation after 5-FU treatment course.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Oct 2017

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 7, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 12, 2017

Completed
28 days until next milestone

Study Start

First participant enrolled

October 10, 2017

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2018

Completed
Last Updated

June 25, 2019

Status Verified

June 1, 2019

Enrollment Period

10 months

First QC Date

September 7, 2017

Last Update Submit

June 24, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Skin barrier biophysical properties

    Transepidermal water loss (TEWL) will be measured using hand-held, noninvasive skin barrier measuring devices (Tewameter)

    2 hours

Study Arms (3)

Topical Steroid Ointment

ACTIVE COMPARATOR

One side of the face will receive a Topical Steroid ointment twice daily for seven days.

Drug: Topical Steroid Ointment

Vaseline

ACTIVE COMPARATOR

One side of the face will receive Vaseline twice daily for seven days.

Other: Vaseline

Skin Barrier Moisturizer

ACTIVE COMPARATOR

One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.

Drug: Skin Barrier Moisturier

Interventions

Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.

Topical Steroid Ointment

Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.

Vaseline

Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.

Skin Barrier Moisturizer

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female, at least 18 years of age
  • Subject must have a diagnosis of actinic keratosis (at least 5 lesions on each side of the face)
  • Able to comprehend and read the English language

You may not qualify if:

  • Concurrently have other inflammatory skin conditions.
  • Prior known allergy to any components to of 5FU cream, topical steroid ointment or vaseline.
  • Subject who, in the opinion of the investigator, will be uncooperative or unable to comply with study procedures (i.e.: compliant with using 5-FU cream, topical corticosteroid or moisturizers
  • Those that are prisoners or cognitively impaired.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Arizona - Banner University Medicine Dermatology

Tucson, Arizona, 85718, United States

Location

MeSH Terms

Conditions

Keratosis, Actinic

Interventions

Petrolatum

Condition Hierarchy (Ancestors)

Precancerous ConditionsNeoplasmsKeratosisSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

HydrocarbonsOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 7, 2017

First Posted

September 12, 2017

Study Start

October 10, 2017

Primary Completion

July 31, 2018

Study Completion

July 31, 2018

Last Updated

June 25, 2019

Record last verified: 2019-06

Data Sharing

IPD Sharing
Will not share

Locations